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Abstract 
 
The multiplexed detection of protein biomarkers in plasma present over a range of clinically 
relevant concentrations continues to be difficult for surface-based bioaffinity detection 
platforms such as surface plasmon resonance (SPR). As well as nonspecific adsorption, 
challenges include quantitative comparison between targets whose concentrations differ by 
orders of magnitude, regenerating SPR chips after plasma exposure as well as the two or four 
channel limitation of many commercial SPR instruments limiting sample throughput. In this 
article, we explore an approach where two protein biomarkers alpha-1 antitrypsin (AAT) and 
Tau 381 are detected in tandem within a single SPR channel at micromolar and femtomolar 
concentrations respectively. This was achieved by creating a mixed antibody (antiAAT and 
antiTau) monolayer on the chip surface. Following the adsorption of AAT and/or Tau, further 
specificity was obtained via the adsorption of a DNA aptamer specific to each target. The 
detection range for each target was controlled via the relative surface density ratio of each 
antibody type as well as each aptamer concentration. Calibration measurements were 
performed in both buffer and spiked plasma with the detection of native concentrations of ~39 
fM (Tau) and ~65 µM (AAT) in a human plasma sample. Finally, tandem measurements of 
both targets within the same SPR signal channel were demonstrated at these very different 
concentrations.   
 
 
Introduction 
The detection of biomarkers in biological fluids (e.g. serum, urine, saliva) has an essential role 
in disease diagnosis and treatment. However, in many cases such as cancer, autoimmune and 
neurodegenerative disease the analysis of only one biomarker is insufficient for valid 
diagnostics,
1-5
 which is not surprising as many proteins operate within complex networks and 
multi-step pathways. This has led to an increasing interest in developing methodologies that 
enable comparative analysis of multiple biomarker levels simultaneously. The most established 
approaches for multiplexed protein biomarker analysis involve either performing a number of 
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individual solution-based measurements in parallel (e.g. enzyme linked immunoassays 
(ELISAÕs)
3,6
 or developing imaging or scanning methods involving bioreceptors immobilized 
on an array chip platform.
1,7
 Other techniques for multiplexed immunoanalysis include 
electrochemical,
8
 microring resonators
9
 and a single molecule ELISA digital array assay.
10
   
 
Surface plasmon resonance (SPR) is a well-established technique for the direct analysis of 
bioaffinity interactions.
11
 However, like all surface-based platforms, the application of SPR to 
molecular diagnostics in serum and other complex media has continued to be challenging due 
to non-specific interactions.
12
 Also, while a number of SPR array based measurement 
configurations are available,
13
 the majority of commercial SPR instruments are typically two 
and four-channel systems. This can contribute to a significant bottleneck in analysis throughput, 
especially for plasma diagnostics where recent work by ourselves
14-16
 have found that the SPR 
chip surface is difficult to regenerate following plasma analysis and cannot be repeatedly used. 
This issue along with the significant number of repeats and controls required also contributes 
to an increased number of SPR chips typically required for plasma analysis. It would also 
potentially help measurement throughput if tandem measurements could be performed within 
a single channel on platforms where the opportunity to create multiple spatially separated probe 
regions is limited. This concept has been little explored in the literature with examples of 
controlling the surface density of mixed DNA probes
17
 but we are not aware of a study 
demonstrating the application of mixed monolayers of two antibody probes.  
 
In this paper, we explore the creation of mixed bioreceptor monolayers on a single sensing 
surface to address the challenge of increasing sample analysis throughput. Specifically, we 
demonstrate that it is possible to achieve wide dynamic range sensing of two different protein 
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biomarkers at clinically relevant concentrations within the same SPR detection channel. This 
was achieved by creating a dual antibody probe layer as part of a multiplexed sandwich assay 
with DNA aptamers introduced to the SPR chip surface following exposure to the target 
proteins. Used in this study was (i) Tau protein (the Tau-381 isoform), which is important in 
neurodegenerative diseases such as AlzheimerÕs,
18
 and (ii) alpha-1 antitrypsin (AAT), where 
high or deficient
19
 levels are associated with various conditions such as lung
20
 and AlzheimerÕs 
disease.
21
  The selection of Tau and AAT as a model system was also based on each having 
very different native concentrations (femtomolar
22
 and micromolar
23
 respectively) in the 
plasma of healthy patients as well as each having established high affinity antibody/aptamer 
assay pairings.
15,16
 In addition to creating a mixed monolayer of antiTau and antiAAT on the 
SPR chip surface, the concentration of the aptamers specific to each target were also optimized 
in order to detect both protein targets on the same chip surface at very different concentrations. 
A series of spiked plasma measurements were performed with the resulting calibration utilized 
to determine the native concentrations of both target proteins present in a human plasma sample.  
 
Experimental Section 
Further experimental details are provided in the Supporting Information. Briefly, recombinant 
Human Tau381 full length protein (Tau) and tau antibody (antiTau) were acquired from Abcam. 
Also, both alpha-1 antitrypsin (AAT) and alpha-1 antitrypsin antibody (antiAAT) were obtained 
from R&D systems. A 5'-amine modified DNA aptamer
24
 specific to Tau, whose sequence is 
5'-H2N-GCGGAGCGTGGCAGG-3' and a 5'-amine modified DNA aptamer25 specific to AAT, 
whose sequence is 5'-H2N-GGG GCA CGT ACG GGC ATC ATA ACA ACA GGC GTG CCC 
C-3' were purchased from Integrated DNA Technologies.  Also, 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimde hydrochloride (EDC, Thermo), N-
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hydroxysulfosuccinimide (NHSS, Thermo Scientific), 11-mercaptoundecanoic acid (MUA, 
Sigma-Aldrich), and plasma from human (Sigma-Aldrich) were all used as received. The 
proteins used for control measurements were immunoglobulin G (IgG; Sigma-Aldrich) and 
bovine serum albumin (BSA; Calbiochem). All in-situ SPR bioaffinity measurements were 
performed using a Biacore 3000 with a flow rate of 5 µL/min employed for all experiments. 
Different concentrations of AAT or Tau solution were individually flowed over the 
functionalized SPR chips for a minimum of 1 h to ascertain a steady-state surface coverage for 
both specific and non-specific binding experiments. Plasma samples were also injected across 
the antibody chip surface for at least 1 h followed by rinsing with PBS buffer. The DNA 
aptamers for either AAT or Tau were suspended at various concentrations in 1x PBS buffer (pH 
7.4) and flowed over the SPR chip for 40 mins followed by washing with PBS buffer for 15 
mins. For AAT or Tau measurements in undiluted or 1,000 times diluted plasma the antibody 
surface could not be completely regenerated after a single measurement. Thus, all plasma 
measurements reported were performed with a freshly prepared chip surface. Each data point 
reported is the average of a minimum of three repeat measurements. 
 
Results and Discussion 
Detection of AAT and Tau Proteins using a Mixed Antibody Chip: The strategy for detecting 
two biomarkers (Tau and AAT) simultaneously in a single detection microchannel is outlined 
in Figure 1. The gold SPR chip surface was first functionalized with a monolayer of 11-
mercaptoundecanoic acid (MUA) to which the corresponding antibodies (antiTau and antiAAT) 
were covalently coupled via EDC/NHSS linking chemistry via an amine group on the antibody 
surface with the relative surface coverage of each antibody systematically varied. Specific 
adsorption measurements for both targets were performed first in buffer and then demonstrated 
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in spiked human plasma solution. The SPR detection signals for both targets were then further 
enhanced by flowing the corresponding DNA aptamer specific to either Tau or AAT (in buffer 
solution) across the chip surface. This binds to a different epitope site on the respective target 
to complete the formation of a sandwich assay.    
 
Figure 1. Schematic overview of strategy for dual detection of AAT and Tau proteins on a single surface. 
Mixed monolayers of antiAAT and antiTau were first immobilized on a MUA modified SPR chip. 
Specific adsorption of AAT and Tau proteins were monitored followed by the subsequent binding of 
AAT aptamer and Tau aptamer. Images representative of AAT and Tau proteins are reproduced from 
refs 
26
 and 
27
, respectively. 
 
In order to successfully detect both targets quantitatively that differ in both concentration and 
the strength of the affinity interaction between the target and respective probes, it is essential 
that the relative surface densities of both antibodies in the mixed monolayer are well-controlled. 
This was achieved during the covalent coupling of the capture antibodies onto the SPR chip 
where the total antibody concentration introduced to the microfluidic chip was fixed at 10 µM 
and the stoichiometric ratio of both antiAAT and antiTau were systematically varied between 
0 and 100%. This approach does assume that the resulting surface density of each antibody on 
the SPR chip closely follows the bulk ratios utilized in the reaction solution.   
Au chip
(i) EDC/NHSS
(ii) antiTau & antiAAT
AAT  aptamer 
Tau  aptamer 
AAT
Tau
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The sensing performance of SPR chips incubated with different molecular ratios of antiAAT 
and antiTau were investigated by performing an extensive series of real-time SPR 
measurements systematically varying both the AAT and tau target concentration and the mixed 
antibody monolayer composition. Some representative SPR response curves for these 
measurements are shown in the supporting information (Figure S1). Also, a series of D R. U. 
plots were generated (see Figure S2) by systematically exposing a range of AAT or Tau 
concentrations to nine different mixed monolayer chip surfaces. These were systematically 
varied from 100% coverage of only one antibody and diluted down to mixtures containing 20% 
of the antibody specific to the target species being monitored.  
 
Figure 2 represents a succinct approach to comparing the results obtained for the various 
combinations of mixed antibody monolayers and protein target concentrations distributed 
across the eighteen data series shown in Figure S2. Each SPR chip monolayer configuration 
was analyzed to establish a target concentration at which the R.U. response is close to saturation 
(i.e. beyond the linear response with minimal further change in SPR signal with increasing 
concentration) is extracted for each mixed antibody monolayer combination. This 
concentration is then normalized with respect to the concentration associated with the signal 
saturation for the 100% antiAAT or antiTau monolayer creating the y-axis ratio in Figure 2 
ranging between 0 and 1. The resulting plot highlights how the availability of surface binding 
sites and sensing performance vary as a function of the mixed monolayer composition. For 
example, at an antiAAT : antiTau ratio of 20 : 80, the AAT detection saturation concentration 
is about 40 nM compared to ~120 nM for Tau detection. These are normalized respectively to 
saturation concentrations of 500 nM and 200 nM for 100% antiAAT and 100% antiTau surfaces.  
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Figure 2. Plot of the saturation concentration ratio for AAT and Tau binding onto a range of mixed 
monolayer surfaces.  
 
As the relative surface densities of both capture antibodies vary, Figure 2 confirms that each 
target protein can still be selectively measured on a multiplexed chip surface and highlights 
how the measurement dynamic range becomes more limited as the density of the antibody 
capture agent is reduced. It is clear that a more marked difference between 100% and 80% 
antiAAT coverage is observed compared to the same change in antiTau coverage with the Tau 
detection dynamic range decreasing more gradually as the fractional coverage of antiTau is 
reduced. The differences in the two plots in Figure 2 may be associated with factors such as 
the antibody surface coupling efficiency affecting the relative surface coverage of each 
antibody or differences in binding affinity. The adsorption coefficient (Kads) for AAT onto a 
100% antiAAT layer was determined to be 7.95(±0.4) ! 10
6
 M
-1
 (Figure S3a) while a Kads of 
3.9(±0.3) ! 10
7
 M
-1
 was determined for Tau adsorption onto a 100% antiTau surface (see Figure 
S3b). These values agree well with previous measurements performed by us
15,16
 and others.
28
  
 
Sandwich assay on mixed monolayer chips. The study on the different mixed monolayer 
configurations clearly showed that both Tau and AAT could be detected at nanomolar 
Tau saturation ratio
AAT saturation ratio
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concentrations on surfaces featuring a mixture of antibodies specific to both targets. In order 
to further improve sensitivity and selectivity, a sandwich assay was applied and we investigated 
this on three different surfaces with antiAAT:antiTau ratios of 30:70, 50:50, and 70:30. Figure 
3 compares a series of plots where a range of concentrations of DNA aptamer specific to either 
AAT (3a-c) or Tau (3d-f) was flowed across different SPR chips that had been previously 
exposed to a fixed protein target concentration. The choice of fixed AAT or Tau concentration 
was based on the results used to generate Figure 2, selecting a value that corresponds to a high 
fractional surface coverage. Each D R. U. data point in Figure 3 was obtained by taking the 
average change in R. U. signal comparing before and after target binding in buffer solution 
only (see Figure S4 for corresponding R. U. curves). In each chip, target binding is monitored 
in two of the available four measurement channels available on each SPR chip with the 
remaining two SPR channels used to perform a series of control measurements. The final D R. 
U. values plotted is the difference between the averaged detection and control channel signals 
acquired over three repeat sets of measurements. A summary of the different negative control 
(NC) measurements used in shown in the supporting information (Table S2) involving repeat 
measurements in the absence of either Tau or AAT target (NC1) or instead introducing BSA 
(NC2) or IgG (NC3) in place of the target protein. Representative R. U. plots from NC control 
channels are also shown in the supporting information (Figure S5). In the measurements 
performed, we also saw no non-specific interaction between the Tau aptamer and antiAAT and 
AAT with the same applied in reverse with AAT aptamer not interacting with antiTau or Tau.  
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Figure 3. Comparing change in SPR signals obtained upon introducing different concentrations of DNA 
aptamer specific to AAT (a, b, c) and Tau (d, e, f) on chip surfaces prepared with three different antiAAT : 
antiTau ratios of 30:70, 50:50 and 70:30. In each case, the chip surface was first exposed to a fixed 
target protein concentration (which is stated in each plot) for a minimum of 1 hr prior to introducing the 
aptamer. The dotted line in each plot indicates the linear SPR response range region.  
 
The results in Figure 3 provides evidence that both the DNA aptamer and antibody pairings for 
the AAT and Tau protein targets bind simultaneously via different epitope sites. Similar 
measurements were also performed on 100% antiAAT and 100% antiTau surfaces (see Figure 
S6). These represent the largest fractional antibody coverages possible in both cases and it can 
be seen that a linear SPR response is obtained for an aptamer concentration range between 
~10Ð200 nM, above which the signal does not change significantly. For the mixed monolayer 
measurements in Figure 3 it can be seen that the D R. U. response is saturated at considerably 
lower DNA aptamer concentrations e.g. for the 70:30 antiAAT : antiTau surface, AAT and Tau 
aptamer concentrations of ~100 nM and ~20 nM would be sufficient to produce close to the 
maximum enhancement of the SPR signal upon sandwich assay formation. In addition, as the 
100 nM
AAT
(b)
(e)
30 nM
Tau
(c)
(f)
150 nM
AAT
17 nM
Tau
(a)
(d)
45 nM
AAT
100 nM
Tau
antiAAT : antiTau = 30 : 70
antiAAT : antiTau = 30 : 70
antiAAT : antiTau = 50 : 50
antiAAT : antiTau = 50 : 50
antiAAT : antiTau = 70 : 30
antiAAT : antiTau = 70 : 30
R2 = 0.998
R2 = 0.978
R2 = 0.991
R2 = 0.976
R2 = 0.993
R2 = 0.948
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antibody ratio is changed to 50:50 and 30:70 the aptamer concentrations associated with signal 
saturation are lower for AAT and higher for Tau detection.   
  
Further experiments were then performed to tailor the measurement range for both target 
proteins by controlling both the surface antibody ratio and DNA aptamer concentrations. A 
significant challenge is being able to detect both targets on the same surface at very different 
concentration ranges. In clinical samples, AAT samples are typically at ~24 Ð 35 µM levels,
23,29
 
while for Tau measurements in healthy patients, analysis capabilities in the 100 fM range is 
required.
22
  To achieve dual detection on the same surface at such large differences in 
concentration, an antiAAT : antiTau ratio of 30 : 70 was selected. Figure S7 shows the results 
of measurements performed at a fixed concentration of (a) 30 nM AAT and (b) 100 fM Tau 
with the target specific DNA aptamer concentration systematically varied in each case. Based 
on these results, AAT aptamer and Tau aptamer concentrations of 30 nM and 100 nM 
respectively were established for performing clinically relevant measurements in human 
plasma.     
 
Plasma measurements. Prior to performing the multiplexed detection of both target species, 
a series of individual measurements were performed where Tau or AAT were spiked into human 
plasma over a range of concentrations. These results are shown in Figure 4 using the optimum 
antiAAT : antiTau surface monolayer ratio of 30 : 70 and concentrations of the specific DNA 
aptamers established earlier. Representative R. U. plots are shown in figs. 4(a) and 4(c) for both 
spiked, nonspiked and control measurements in plasma. In the corresponding D R. U. plots in 
Figure 4(b) and 4(d) a set of measurements acquired in buffer only is shown alongside the 
plasma data series. In both sets of data the D R. U. signals were consistently higher for plasma
12 
 
which can be associated with non-specific adsorption. In the case of the Tau measurements 
(Figure 4d) both the plasma and buffer series indicate similar linearity indicated by the dotted 
lines (1.14 versus 0.96 D R. U./fM for plasma and buffer respectively). This suggests the 
amount of nonspecific adsorption in the nondiluted plasma is relatively constant for all 
measurements. For the diluted plasma measurements in Figure 4(b), there is a bigger difference 
between the plasma and buffer slope fits (1.04 versus 1.64 D R. U./nM respectively). Thus, in 
both data sets the linear fit of the spiked plasma measurements was used to estimate the native 
AAT and Tau concentrations. This is described in more detail in the supporting information 
with values of 39(± 5) fM for Tau and 65(± 8) µM for AAT obtained. Both of these values are 
in the range expected, as discussed above, with the AAT concentration also taking into account 
the 1000-fold dilution of the plasma stock prior to measurement and spiking.   
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Figure 4. SPR measurements in plasma for (a), (b) AAT and (c), (d) Tau measurements in both spiked 
and native plasma (P) performed on a antiAAT : antiTau 30 : 70 chip surface. Representative SPR 
sensorgrams are shown in (a) and (c) following exposure to plasma (both spiked and native) alongside 
examples of negative controls BSA, IgG spiked at 25 nM in (a) and 100 fM in (c). For the AAT samples, 
the plasma was first diluted 1000-fold in buffer before spiking, while for the Tau measurements 
undiluted plasma is used directly. In (b) and (d), the dotted line is a guide for the linear response range 
with the plasma only (P) and spiked P data points indicated separately.   
 
 
A final set of experiments were performed to demonstrate the dual detection of both targets 
concurrently within the same SPR detection channel. This was achieved by exposing the 30:70 
antiAAT:antiTau surface to a mixture of both targets for at least one hour before then 
sequentially flowing each of the target aptamers across the SPR chip. Figure 5(a) shows 
representative R. U. plots in 1000-fold diluted plasma for both plasma only as well as spiked 
at two different AAT and Tau concentrations. Additional R. U. sensorgrams are also shown in 
(d)(c) Buffer
P+50fM
P+100fM
P+150fM
Plasma
(a) Buffer
P+15nM
P+45nM
Plasma
P+25nM
(b)
dil. P spiked
AAT
aptamer
45 nM
Tau
aptamer
100 nM
P
antiAAT : antiTau = 30:70
antiAAT : antiTau = 30:70
BSA IgG
BSA
IgG
AAT
Tau
AAT aptamer
Tau aptamer
dil. P
P spiked
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Figure S9 (supporting information) for the measurements in spiked buffer and nondiluted 
plasma.  
 
  
Figure 5. Comparison of concurrent SPR measurements of AAT and Tau performed in plasma (P), 
1000x-diluted plasma (dil. P) and buffer. (a) R. U. plots performed on a antiAAT : antiTau 30 : 70 chip 
surface which was exposed to 1000-fold diluted plasma, both spiked and plasma only, for at least one 
hour prior to the sequential introduction of aptamers specific to AAT and Tau. (b) D R. U values obtained 
for AAT and (c) Tau obtained for dual target measurements. The data series acquired in buffer in Figure 
4(b) and 4(d) are shown again here (black data points) for comparison with the dual detection data 
points in plasma (blue), dil. P (red) and buffer (green).     
 
The D R. U. values obtained from analysis of the sensorgrams (in Figure 5(a) and Figure S9) 
are shown in Figure 5(b) and (c), which focus on AAT and Tau detection separately. Also 
shown alongside the dual detection measurements are the buffer calibration values from Figure 
AAT aptamer 
45 nM
Tau aptamer 
100 nM
(a)
(c)(b)
dil. P spike
dil. P
dil. P spike
P
P spike
buffer
spike
dil. P
P dil. P spike
dil. P spike
buffer 
spike
AAT
aptamer
45 nM
Tau
aptamer
100 nM
1000x diluted P
A. Plasma only
B. P + AAT 15 nM, Tau 50 fM
C. P + AAT 45 nM, Tau 150 fM
Buffer
Buffer
C
B
A
15 
 
4(b) and (d). The dual spiked buffer experiments were performed at concentrations of (10 nM 
AAT, 70 fM Tau) and (45 nM AAT, 150 fM Tau) and the D R. U. values obtained show good 
overlap with the previous single target measurements. This supports the assertion that there is 
no significant desorption of the Tau target during the AAT aptamer binding step before 
introducing the Tau aptamer. In the subsequent analysis of the diluted plasma (15 nM AAT, 50 
fM Tau) and (45 nM AAT, 150 fM Tau) the AAT D R. U. values are similar to that obtained 
in Figure 4(b), while the signal using nondiluted plasma is saturated beyond the SPR linear 
response range. For Tau detection, a D R. U. of close to zero is obtained for the diluted plasma 
(without spiking), which was expected as the native concentration here will be too low to detect. 
Good reproducibility compared to that observed in Figure 4(d) was also observed. These results 
confirm that it is possible to perform more complex tandem measurements involving at least 
two different target species within a single SPR detection channel.  
 
Conclusions 
In this article, we demonstrate that two protein biomarker targets can be detected together on 
the same SPR chip surface with both species present at target concentrations differing by 
several orders of magnitude. This was achieved by controlling and optimizing both the ratio of 
the capture antibodies on the chip surface along with the concentration of the secondary DNA 
aptamer capture agents used. As a result, it was possible to detect AAT at nanomolar 
concentrations alongside Tau 381 at femtomolar concentrations within the same SPR detection 
channel. A motivation for this work is that following a measurement in plasma the SPR chip 
surface is difficult to regenerate. For successful measurements in plasma it is essential that 
control measurements are also acquired in parallel reference channels alongside the target. This 
fact, combined with many high-end SPR devices limited to four detection channels, 
16 
 
significantly reduces multiplexing capabilities as well as adding cost and time in the number 
of SPR chips required. The methodology developed here helps to address this problem. In 
future, this work will be extended to more complex analyses such as the introduction of plasma 
at a particular dilution followed by a specific antibody or aptamer and repeating this cycle from 
highly diluted to nondiluted plasma samples. For example, this could be necessary to help 
quantify differences between two targets occurring between healthy and diseased patient 
samples as performing such measurements across the femto- to micro-molar range is still a 
significant challenge.  
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